Several FcRn inhibitors, which selectively target IgG recycling and thus accelerate IgG clearance, have shown promising results in recent clinical trials for managing immune thrombocytopenia (ITP) and myasthenia gravis [11]. The gene discussed is FCGRT; the disease is myasthenia gravis.